UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q/A

(Amendment No. 1)

For the quarterly period ended June 30, 2014

Commission File Number: 001-35642

GlobeImmune, Inc.

(Exact name of registrant as specified in its charter)

(303) 625-2700

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.*    Yes  o    No  þ

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  þ    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  o    No  þ

As of August 1, 2014, the registrant had 5,748,979 shares of common stock, $0.001 par value per share, outstanding.

EXPLANATORY NOTE

GlobeImmune, Inc. is filing this Amendment No. 1 to the quarterly report of GlobeImmune, Inc. on Form 10-Q/A (this “Amendment”) to amend our Quarterly Report on Form 10-Q for the three month period ended June 30, 2014 , as filed with the Securities and Exchange Commission (the “SEC”) on August 15, 2014 (the “Form 10-Q”). This Amendment is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.  In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as exhibits to this Amendment. Unless the context requires otherwise, references in this Amendment to “GlobeImmune,” “we” and “our” refer to GlobeImmune, Inc.

Except as described above, no other changes have been made to the Form 10-Q. This Amendment to the Form 10-Q speaks only as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify, update or change in any way the disclosures made in the Form 10-Q.  Accordingly, this Amendment should be read in conjunction with our filings made with the SEC subsequent to the filing of the Form 10-Q, including any amendments to such filings.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

3

EXHIBIT INDEX

4